Erasca announces ‘promising’ early clinical data for ERAS-0015

Erasca (ERAS) “announced meaningful clinical progress for its RAS-targeting franchise and 2026-2027 milestones.” “With both ERAS-0015 and ERAS-4001 INDs previously cleared in May 2025, Erasca’s strong operational execution continues to result in rapid clinical advancement of our RAS-targeting franchise. Notably, ERAS-0015 is now enrolling ahead of plan, thus providing early clinical data,” said Jonathan E. Lim, CEO, and co-founder. “During dose escalation, ERAS-0015 has already demonstrated promising early clinical activity with multiple ongoing confirmed and unconfirmed responses achieved, along with encouraging safety and tolerability data and well-behaved PK. We believe that observing first clinical responses in multiple patients at just 1/10th of the dose at which first clinical responses were observed with RMC-6236 is thesis-reinforcing in terms of ERAS-0015’s potential differentiation.”